Jaguar Health Registers 41M Shares for Resale Under $40M Equity Line — Potential 89% Dilution
JAGX is trading near its 52-week low of $0.97 (5.2% above the low).
Summary
Jaguar Health registered 41 million shares for resale under its $40M equity line, creating potential dilution of over 89% if fully utilized. The filing confirms deeply discounted purchase mechanics and $800K in commitment shares payable to the investor.
Key Events · Financing and Capital Events · JAGX
-
41M Share Resale Registration
The S-1 registers resale of up to 41,000,000 shares under the $40M equity line with C/M Capital — if all issued, they would represent over 89.3% of the 4.9M shares currently outstanding.
-
Deeply Discounted Purchase Mechanics
VWAP purchases are priced at 95% of the lowest of the VWAP, the 5-day low, or the closing price — guaranteeing the investor always buys at a discount to market, creating immediate resale incentive.
-
$800K Commitment Shares Due
Upon registration effectiveness, the company must issue $800,000 worth of common stock to the investor as Commitment Shares — additional dilution with no cash proceeds to Jaguar.
-
Series P Preferred Stock Financing
A concurrent $2M private placement of Series P Preferred Stock includes pre-funded warrants for $72,000 in shares, adding further potential dilution.
Analysis · JAGX · Life Sciences
An S-1 filed by Jaguar Health registers the resale of up to 41 million shares under its $40 million equity line with C/M Capital. If fully drawn and sold, these shares would represent over 89% of the current outstanding, creating a massively dilutive overhang. The filing reveals that the investor always buys at a discount — VWAP purchases are priced at 95% of the lowest recent price — and the company must issue $800,000 in Commitment Shares just to activate the facility. Against a backdrop of recent Nasdaq compliance struggles and a $5M market cap, this registration makes the dilution threat concrete and tradable, giving the investor a clear path to sell into any strength.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 36.8% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $1.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.97 to $92.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.